stocks logo

RPRX

Royalty Pharma PLC
$
36.670
+0.08(0.219%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.710
Open
36.650
VWAP
36.51
Vol
1.93M
Mkt Cap
20.62B
Low
36.290
Amount
70.36M
EV/EBITDA(TTM)
15.53
Total Shares
452.11M
EV
29.52B
EV/OCF(TTM)
10.93
P/S(TTM)
9.55
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
705.46M
+31.37%
1.023
+6.39%
784.63M
+38.87%
0.999
-3.95%
770.48M
+29.71%
1.273
+10.56%
Estimates Revision
The market is revising Downward the revenue expectations for Royalty Pharma plc (RPRX) for FY2025, with the revenue forecasts being adjusted by -1.81% over the past three months. During the same period, the stock price has changed by 12.69%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.81%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.4%
In Past 3 Month
Stock Price
Go Up
up Image
+12.69%
In Past 3 Month
4 Analyst Rating
up Image
19.31% Upside
Wall Street analysts forecast RPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPRX is 43.75 USD with a low forecast of 40.00 USD and a high forecast of 51.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
up Image
19.31% Upside
Current: 36.670
sliders
Low
40.00
Averages
43.75
High
51.00
Citi
Buy
maintain
$40 -> $42
2025-07-22
Reason
Citi raised the firm's price target on Royalty Pharma to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Morgan Stanley
Terence Flynn
Overweight
maintain
$51 -> $54
2025-07-10
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Royalty Pharma to $54 from $51 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Morgan Stanley
Overweight
initiated
$51
2025-05-16
Reason
Morgan Stanley resumed coverage of Royalty Pharma with an Overweight rating and $51 price target. The firm cites se the company's diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Citigroup
Andrew Baum
Strong Buy
Maintains
$60 → $40
2024-10-25
Reason
Goldman Sachs
Chris Shibutani
Strong Buy
Maintains
$50 → $51
2024-08-14
Reason

Valuation Metrics

The current forward P/E ratio for Royalty Pharma PLC (RPRX.O) is 7.99, compared to its 5-year average forward P/E of 10.56. For a more detailed relative valuation and DCF analysis to assess Royalty Pharma PLC 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
10.56
Current PE
7.99
Overvalued PE
14.05
Undervalued PE
7.07

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
10.67
Current EV/EBITDA
8.83
Overvalued EV/EBITDA
12.88
Undervalued EV/EBITDA
8.45

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
6.12
Current PS
5.00
Overvalued PS
7.54
Undervalued PS
4.71

Financials

Annual
Quarterly
FY2025Q1
YoY :
+0.05%
568.25M
Total Revenue
FY2025Q1
YoY :
-824.08%
534.18M
Operating Profit
FY2025Q1
YoY :
-10243.53%
433.43M
Net Income after Tax
FY2025Q1
YoY :
+5400.00%
0.55
EPS - Diluted
FY2025Q1
YoY :
+2.85%
595.02M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
-72.84%
12.36
FCF Margin - %
FY2025Q1
YoY :
-10270.67%
76.28
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 100.83% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.6M
Volume
3
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
5.2M
Volume
Months
6-9
6
2.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RPRX News & Events

Events Timeline

2025-07-17 (ET)
2025-07-17
08:23:22
Royalty Pharma appoints Ho, Weatherman to board of directors
select
2025-06-24 (ET)
2025-06-24
07:15:30
Royalty Pharma announces $2B funding arrangement with Revolution Medicines
select
2025-06-24
07:13:36
Revolution Medicines enters $2B funding agreement with Royalty Pharma
select
Sign Up For More Events

News

8.0
07-18Yahoo Finance
Royalty Pharma Declares Third Quarter 2025 Dividend
5.0
07-17Newsfilter
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
5.0
07-17Yahoo Finance
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors
Sign Up For More News

FAQ

arrow icon

What is Royalty Pharma PLC (RPRX) stock price today?

The current price of RPRX is 36.67 USD — it has increased 0.22 % in the last trading day.

arrow icon

What is Royalty Pharma PLC (RPRX)'s business?

arrow icon

What is the price predicton of RPRX Stock?

arrow icon

What is Royalty Pharma PLC (RPRX)'s revenue for the last quarter?

arrow icon

What is Royalty Pharma PLC (RPRX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Royalty Pharma PLC (RPRX)'s fundamentals?

arrow icon

How many employees does Royalty Pharma PLC (RPRX). have?

arrow icon

What is Royalty Pharma PLC (RPRX) market cap?